Search press releases
Every release here is real and links to its original. Filter by company, topic, language and date.
- MUVON Therapeutics Reports Positive 12-Month Phase 2 Follow-up Data Confirming Durable Efficacy of its First-in-Class Muscle Regeneration Therapy in Stress Urinary IncontinenceMUVON Therapeutics AG, a clinical-stage biotechnology company, reports positive 12-month interim results from the Long-Term Follow-Up Study of the Phase 2 clinical trial SUISSE-MPC2 (NCT05534269), demonstrating durable, sustained and clinically relevant bladder health benefits in patients treated with its novel proprietary muscle precursor cell (MPC)-based tissue-engineered therapy for female stress urinary incontinence (SUI). SUI represents a high unmet medical need, affecting more than 150 million women worldwide, for which no approved therapy presently addresses the underlying cause. The study results were presented in an oral session at the Annual Meeting of the International Continence Society (ICS) in Maastricht, the Netherlands, on October 7, 2026 [1].
- ITM and Lumara Bio to Announce New Data for ¹⁷⁷Lu-edotreotide (ITM-11) and Ga-DPI-4452 at EANM 2026Garching / Munich, October 7, 2026 — ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Lumara Bio, a dedicated oncology therapeutics division of ITM, today announced that new data for 177Lu-edotreotide (ITM-11) and Ga-DPI-4452 (CA-IX peptide) will be unveiled in two top-rated oral presentations at the European Association of Nuclear Medicine (EANM) Congress, held from October 17 – 21, 2026 in Vienna, Austria. Anthime Flaus, MD, PhD, of the Hospital Louis Pradel in Bron, France will present dose-response findings from the Phase 3 COMPETE trial, in which patients with gastroenteropancreatic neuroendocrine tumors were treated with 177Lu-edotreotide. Alina Küper, MD, of the University Hospital Essen in Germany will present interim results from an independent, retrospective analysis of the PET/CT imaging agent Ga-DPI-4452 (CA-IX peptide) used for the imaging of clear cell renal cell carcinoma in a bicenter registry. In addition to the scientific presentations, ITM will host a booth reception and separate Meet the Expert session. At this session, Dr. Neil Quigley will share insights into the production of Actinium-225 (225Ac) using medium-energy cyclotrons and present Actineer’s approach to increase production capacity. Actineer is the joint venture between ITM and Canadian Nuclear Laboratories. Oral Presentation Details Title: Ga-DPI-4452 (CA-IX peptide) PET/CT for Imaging Clear Cell Renal Cell Carcinoma: Interim Results from a Bicentre Registry Session Title: Renal Cell Cancer and Novel Targets Session Number: 506 Track: Clinical Oncology Date and Time: Sunday, October 18, 2026, 15:00 – 16:30 CEST Location: Hall C Presenter: Dr. Alina Küper, University Hospital Essen, Essen, Germany Title: Dose-response Analysis in Patients with Gastroenteropancreatic Neuroendocrine Tumors Receiving [¹⁷⁷Lu]Lu-edotreotide Session Title: From Clinical Dosimetry to Treatment Adaptation in [¹⁷⁷Lu] Therapy Session Number: 1505 Track: Cutting Edge Science Date and Time: Tuesday, October 20, 2026, 15:00 – 16:30 CEST Location: Hall B Presenter: Dr. Anthime Flaus, Hospital Louis Pradel, Bron, France Meet the Expert Session Title: 225Ac Production via Medium-Energy Cyclotrons: Actineer’s Path Towards Increasing Production Capacities Date and Time: Monday, October 19, 2026, 10:30 – 10:50 CEST Location: ITM Booth #415, Hall X4 Presenter: Dr. Neil Quigley, Radioisotope Scientific Expert at ITM Conference attendees will have the opportunity to learn more about ITM and Lumara Bio, a division of ITM, by visiting the company booth, #415 in Hall X4. Attendees are also invited to join the ITM team for an informal booth reception and networking opportunity on Monday, October 19, from 16:00 to 17:00 CEST. 177Lu-edotreotide (ITM-11) and Ga-DPI-4452 (CA-IX peptide) are investigational products and are not approved by any regulatory authority for the safety and/or efficacy of any intended use. About the COMPETE Trial The COMPETE trial (NCT03049189) evaluated 177Lu-edotreotide (ITM-11), a proprietary, synthetic, targeted radiotherapeutic investigational agent compared to everolimus, a targeted molecular therapy, in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This trial met its primary endpoint, with 177Lu-edotreotide demonstrating clinically and statistically significant improvement in progression-free survival (PFS) compared to everolimus. 177Lu-edotreotide is an investigational product and is not approved by any regulatory authority for the safety and/or efficacy of any intended use. 177Lu-edotreotide is also being evaluated in COMPOSE, a Phase 3 study in patients with well-differentiated, aggressive Grade 2 or Grade 3, somatostatin receptor (SSTR)-positive GEP-NETs. About Ga-DPI-4452 (ITM-94) Ga-DPI-4452 (also known as [68Ga]Ga-DPI-4452, CA-IX peptide, or ITM-94) is an investigational gallium-68-radiolabeled PET imaging agent targeting carbonic anhydrase IX (CAIX), a cell surface protein that plays a key role in tumor growth, invasion, and metastasis. ITM-94 is designed to non-invasively improve the characterization of indeterminate renal masses and enable more accurate diagnosis and disease staging of clear cell renal cell carcinoma (ccRCC). ITM-94 received Fast Track Designation from the FDA in October 2025. [68Ga]Ga-DPI-4452 is an investigational product and is not approved by any regulatory authority for the safety and/or efficacy of any intended use. About ITM Isotope Technologies Munich SE ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply of medical radioisotopes. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. www.itm-radiopharma.com About Lumara Bio Lumara Bio, a division of ITM, builds on more than two decades of radiopharmaceutical expertise and is advancing a focused pipeline of targeted therapies for cancers where treatment options remain limited. https://lumarabio.com ITM Contact Corporate Communications Kathleen Noonan/Julia Westermeir Phone: +49 89 329 8986 1500 Email: [email protected] Investor Relations Ben Orzelek Phone: +49 89 329 8986 1009 Email: [email protected]
- LG CNS Showcases Pharma-Specific Manufacturing AX at World's Largest Pharma-Biotech ShowParticipates in CPHI Milan 2026, Expanding Manufacturing AX Reach in Pharma Showcasing key solutions for factory design, production operations, and quality management using the theme "Autonomous Factory in Pharma" SEOUL, South Korea and MILAN, Oct. 7, 2026 -- LG CNS, a...
- OncoBayesOncoBayes progressing OB-001 to tackle ADC resistance and TKI brain penetrationOncoBayes, a privately held clinical-stage pharmaceutical company, today announced the successful completion of preclinical work with OB-001, demonstrating the product's potential to tackle two major unmet needs in oncology: ADC resistance and the...
- Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic LeukemiaFirst patient enrolled in cohort combining bexobrutideg with venetoclax
- Palindrome Pharma Inc.Palindrome Pharma Launches in Canada to Unlock Access to High-Quality Biosimilar MedicinesPalindrome Pharma, a new pharmaceutical company focused on biosimilar medicines, today announced its launch in Canada, with a mission to broaden access to high-quality biologic therapies and contribute to a more sustainable Canadian healthcare system.As demand for biologic medicines continues to grow, biosimilars have an important role to play in creating greater choices for Canadians. Palindrome Pharma will work with global and Canadian...
- ComplianceQuestComplianceQuest 與 Zolon PCS 獲選負責美國食品藥物管理局（FDA）企業品質管理系統的現代化改造領先的人工智慧驅動型「互聯品質、風險與合規（QRC）」系統供應商 ComplianceQuest，以及專為聯邦機構提供安全且以任務為導向的 IT 服務供應商 Zolon PCS，今日宣布美國食品藥物管理局（FDA）將透過 Comp
- Harbor HealthHarbor Health aúna atención sanitaria y cobertura en Houston con la adquisición de Village Medical ClinicsLas 27 clínicas de Village Medical Houston se unen a Harbor para convertirse en el centro de atención de los planes de Harbor, que no tienen franquicia; la inscripción individual y familiar se abre el 1 de noviembre, junto con los planes de grandes empresas de todo Texas. HOUSTON, 6 de...
- The Rosen Law Firm PAROSEN, A LEADING NATIONAL FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMSWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Hims securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...
- Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior NotesVaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of concurrent underwritten public offerings of 7,412,500 shares of common stock, pre-funded warrants to purchase 400,000 shares of common stock and $500 million aggregate principal amount of 1.50% convertible senior notes due 2032 (the “notes”). The shares of common stock are being sold at a public offering price of $64.00 per share, and the pre-funded warrants are being sold at a public offering price of $63.999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.001 per share. The shares of common stock, pre-funded warrants and notes to be sold in the offerings are being offered by Vaxcyte. Vaxcyte has granted the underwriters of the common stock and pre-funded warrant offering a 30-day option to purchase up to an additional 1,171,875 shares of its common stock at the public offering price per share, and has granted the underwriters of the note offering a 30-day option to purchase up to an additional $75 million aggregate principal amount of notes at the public offering price, solely to cover over-allotments, in each case less underwriting discounts and commissions.
- Hims & Hers Health, Inc. Securities Fraud Class Action Result of Deceptive Privacy and Billing Practices and Over 14% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLCHims & Hers Health (HIMS) Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit
- Ademi LLPOPCH SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES OPTION CARE HEALTH, INC.Option Care Health shareholders will receive just $32.05 per share, representing a total enterprise value of approximately $5.8 billion; Ademi LLP is investigating the deal price, benefits to company insiders, and restrictions on competing offers CLICK HERE TO JOIN MILWAUKEE, Oct. 6, 2026...